Literature DB >> 1328755

Plasma tumor necrosis factor soluble receptors in chronic renal failure.

M Brockhaus1, Y Bar-Khayim, S Gurwicz, A Frensdorff, N Haran.   

Abstract

Two soluble tumor necrosis factor receptors (sTNFRs) were detected in the plasma of patients with different degrees of chronic renal failure (CRF) and of long-term hemodialysis (HD) patients. In uremic undialyzed patients, plasma levels of both sTNFRs increased progressively with declining renal function. A linear correlation was found between sTNFR plasma levels and plasma creatinine concentration. sTNFR levels in end-stage uremic patients shortly before commencement of first HD treatment were approximately tenfold higher than in normal subjects. Long-term HD patients showed a further increase in plasma sTNFRs. The origin of sTNFRs, as well as their physiological role remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328755     DOI: 10.1038/ki.1992.332

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders.

Authors:  Katsuhito Ihara; Jan Skupien; Bozena Krolewski; Zaipul I Md Dom; Kristina O'Neil; Eiichiro Satake; Hiroki Kobayashi; Narges M Rashidi; Monika A Niewczas; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2020-07-25       Impact factor: 10.612

2.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors:  Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

3.  Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls.

Authors:  A J Staal-van den Brekel; A M Schols; M A Dentener; G P ten Velde; W A Buurman; E F Wouters
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 4.  Does inflammation affect outcomes in dialysis patients?

Authors:  Kristen L Nowak; Michel Chonchol
Journal:  Semin Dial       Date:  2018-03-07       Impact factor: 3.455

5.  Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients.

Authors:  R F Schwabe; H Engelmann; S Hess; H Fricke
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

6.  Increased concentrations of tumour necrosis factor (TNF) and soluble TNF receptors in biliary obstruction in mice; soluble TNF receptors as prognostic factors for mortality.

Authors:  M H Bemelmans; J W Greve; D J Gouma; W A Buurman
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

7.  Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes.

Authors:  Monika A Niewczas; Linda H Ficociello; Amanda C Johnson; William Walker; Elizabeth T Rosolowsky; Bijan Roshan; James H Warram; Andrzej S Krolewski
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

8.  Levels of inhibitors of tumor necrosis factor alpha and interleukin 1beta in urine and sera of patients with urosepsis.

Authors:  D P Olszyna; J M Prins; B Buis; S J van Deventer; P Speelman; T van der Poll
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

Review 9.  Mechanisms of haemolysis-induced kidney injury.

Authors:  Kristof Van Avondt; Erfan Nur; Sacha Zeerleder
Journal:  Nat Rev Nephrol       Date:  2019-08-27       Impact factor: 28.314

10.  The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma.

Authors:  A J Staal-van den Brekel; A M Schols; M A Dentener; G P ten Velde; W A Buurman; E F Wouters
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.